Skip to main content


Media Contacts:


Polina Miklush
Mobile: +1 908 608 7170

CSL Seqirus news releases

CSL Seqirus news releases

New Canadian Surveys Highlight Influenza Education, Discussions with Healthcare Professionals, and Ease of Access as Critical to Supporting Vaccination Uptake

29 Sep 2022

Despite high burden of disease, influenza continues to suffer from perceived lack of risk, contributing to low vaccine uptake among parents and Canadian adults

Seqirus Ready to Reinforce Canada’s Influenza Pandemic Preparedness Plans

23 Mar 2021

Health Canada’s Approval of FOCLIVIA® (An Adjuvanted, Egg-Based A Strain H5N1 Pandemic Influenza Vaccine) Meets Key Requirement as Pandemic Partner

Seqirus Presents Key Insights on Influenza Vaccines at the Canadian Immunization Conference 2020

02 Dec 2020

Absolute Efficacy of Cell-Based Influenza Vaccines in Children Aged 2 to 18 Years, Impact of COVID-19 on Canadians’ Views of Influenza, Among Data Being Presented

COVID-19 Update

02 Apr 2020

Safeguarding our people and communities remains our top priority.

Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine

11 Dec 2019

/CNW/ - Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine (QIVc) has received approval from Health Canada for use in people 9 years of age and older. Marketed as FLUCELVAX® QUAD, the vaccine offers protection against four influenza virus strains — A(H3N2), A(H1N1) and two B virus strains1.